Data Year:

For its 2025 fiscal year, EMERGENT BIOSOLUTIONS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Richard Lindahl
Executive Vice President, Chief Financial Officer
Total Compensation $2,708,723 View details Pay Rank By Title In Biotechnology industry #178 View more
Coleen Glessner
Executive Vice President, Quality and Ethics and Compliance
Total Compensation $1,664,258 View details Pay Rank By Title In Biotechnology industry #124 View more
Paul Williams
Senior Vice President, Products Business
Total Compensation $1,391,158 View details Pay Rank By Title In Biotechnology industry #15 View more
Joseph Papa
President, Chief Executive Officer and Director
Total Compensation $5,321,147 View details Pay Rank By Title In Biotechnology industry #252 View more
Simon Lowry
Chief Medical Officer and Head of Research and Development
Total Compensation $1,471,276 View details Pay Rank By Title In Biotechnology industry #227 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at EMERGENT BIOSOLUTIONS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. EMERGENT BIOSOLUTIONS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. EMERGENT BIOSOLUTIONS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Richard Lindahl
Executive Vice President, Chief Financial Officer
Total Cash $1,093,220 Equity $1,605,003 Other $10,500 $2,708,723
Coleen Glessner
Executive Vice President, Quality and Ethics and Compliance
Total Cash $1,029,633 Equity $626,106 Other $8,519 $1,664,258
Paul Williams
Senior Vice President, Products Business
Total Cash $757,627 Equity $626,106 Other $7,425 $1,391,158
Joseph Papa
President, Chief Executive Officer and Director
Total Cash $2,484,025 Equity $2,830,000 Other $7,122 $5,321,147
Simon Lowry
Chief Medical Officer and Head of Research and Development
Total Cash $834,670 Equity $626,106 Other $10,500 $1,471,276
For its 2025 fiscal year, EMERGENT BIOSOLUTIONS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Joseph Papa CEO Pay $5,321,147 Median Employee Pay $130,553 CEO Pay Ratio 41:1
For its 2023 fiscal year, EMERGENT BIOSOLUTIONS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Donald DeGolyer Total Cash $397,500
General Joulwan Total Cash $41,826
Jerome Hauer, Ph.D. Total Cash $351,372
Kathryn Zoon, Ph.D. Total Cash $413,476
Keith Katkin Total Cash $396,992
Louis Sullivan, M.D. Total Cash $400,233
Marvin White Total Cash $405,975
Neal Fowler Total Cash $398,750
Ronald Richard Total Cash $394,725
Sujata Dayal Total Cash $382,233
Zsolt Harsanyi Total Cash $535,975
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.